• Return to search results
• Start new search

Investigator(s):
William L. Dahut, M.D. Principal Investigator Phone: 301-435-8183 dahutw@mail.nih.gov
Referral Contact(s):
Laura D. Otten, R.N., B.S.N., O.C.N. Medical Oncology Referral Coordinator Phone: 301-451-1228 1-866-611-6310 (Toll Free) Fax: 301-451-5433 ottenl@mail.nih.gov	David Draper, R.N., B.S.N. Research Nurse Phone: 301-435-5614 draperd@mail.nih.gov

---

Primary Eligibility:

• Metastatic androgen independent prostate cancer
• Progressive disease, either radiographically or rising PSA
• No prior chemotherapy for metastatic prostate cancer
• Systolic blood pressure < 170 mmHg and diastolic blood pressure < 100 mmHg
• No proteinuria, defined as a 24-hour urine protein excretion < 300 mg
• No brain metastases
• Age 18 and over
• ECOG 0-2
• Life expectancy of greater than 3 months

---

Study Outline:

• 21-day cycles during which patients receive:
  • Docetaxel every 21 days
  • Bevacizumab every 21 days
  • Daily oral thalidomide beginning with the third cycle
  • Daily oral prednisone beginning with the third cycle
• Study participants will be placed on prophylactic anticoagulation beginning with the third cycle
• Study participants will be seen every 3 weeks at the National Cancer Institute

---

Additional Information:

• This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
• There is no charge for medical care received at NIH Clinical Center.
• FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, treatment plan.
• PDQ (Physicians Data Query) - provides additional details about this study for health care providers.

Reviewed: 9/10/09
Updated: 1/28/09